These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 9572544)
1. Effect of aldose reductase inhibitor on corneal epithelial barrier function in galactose-fed dogs. Kubo E; Mori K; Kobayashi T; Takahashi Y; Yokoi N; Kinoshita S; Kasahara T; Yonezawa H; Akagi Y J Ocul Pharmacol Ther; 1998 Apr; 14(2):181-90. PubMed ID: 9572544 [TBL] [Abstract][Full Text] [Related]
2. Effects of aldose reductase inhibitor CT-112 on the corneal epithelial barrier of galactose-fed rats. Yokoi N; Niiya A; Komuro A; Yokogaki S; Naka H; Awata T; Honma Y; Yamada J; Tei M; Kinoshita S Curr Eye Res; 1997 Jun; 16(6):595-9. PubMed ID: 9192169 [TBL] [Abstract][Full Text] [Related]
3. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors. Jacot JL; Hosotani H; Glover JP; Lois N; Robison WG J Ocul Pharmacol Ther; 1998 Apr; 14(2):169-80. PubMed ID: 9572543 [TBL] [Abstract][Full Text] [Related]
4. Normalization of lens protein kinase Cgamma in galactosemic dogs by a novel aldose reductase inhibitor. Takemoto DJ; Harris R; Brightman A; McGill J; Hua D; Davidson H; Fenwick B; Wagner LM Vet Ophthalmol; 2004; 7(3):163-7. PubMed ID: 15091323 [TBL] [Abstract][Full Text] [Related]
5. Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose. Kador PF; Betts D; Wyman M; Blessing K; Randazzo J Am J Vet Res; 2006 Oct; 67(10):1783-7. PubMed ID: 17014334 [TBL] [Abstract][Full Text] [Related]
6. An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs. Kasuya Y; Ito M; Nakamura J; Hamada Y; Nakayama M; Chaya S; Komori T; Naruse K; Nakashima E; Kato K; Koh N; Hotta N Diabetologia; 1999 Dec; 42(12):1404-9. PubMed ID: 10651257 [TBL] [Abstract][Full Text] [Related]
7. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism. Inaba M; Terada M; Nishizawa Y; Shioi A; Ishimura E; Otani S; Morii H Metabolism; 1999 Jul; 48(7):904-9. PubMed ID: 10421234 [TBL] [Abstract][Full Text] [Related]
8. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. Neuenschwander H; Takahashi Y; Kador PF J Ocul Pharmacol Ther; 1997 Dec; 13(6):517-28. PubMed ID: 9436155 [TBL] [Abstract][Full Text] [Related]
9. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Cusick M; Chew EY; Ferris F; Cox TA; Chan CC; Kador PF Arch Ophthalmol; 2003 Dec; 121(12):1745-51. PubMed ID: 14662595 [TBL] [Abstract][Full Text] [Related]
10. Aldose reductase inhibitor counteracts the enhanced expression of matrix metalloproteinase-10 and improves corneal wound healing in galactose-fed rats. Takamura Y; Matsumoto T; Tomomatsu T; Matsumura T; Takihara Y; Inatani M Mol Vis; 2013; 19():2477-86. PubMed ID: 24339723 [TBL] [Abstract][Full Text] [Related]
12. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs. Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961 [TBL] [Abstract][Full Text] [Related]
13. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175. Sato S; Mori K; Wyman M; Kador PF Exp Eye Res; 1998 Feb; 66(2):217-22. PubMed ID: 9533847 [TBL] [Abstract][Full Text] [Related]
14. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Frank RN; Amin R; Kennedy A; Hohman TC Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227 [TBL] [Abstract][Full Text] [Related]
15. Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235. Fujishima H; Tsubota K Br J Ophthalmol; 2002 Aug; 86(8):860-3. PubMed ID: 12140204 [TBL] [Abstract][Full Text] [Related]
16. Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats. Robison WG; Jacot JL; Glover JP; Basso MD; Hohman TC Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1933-41. PubMed ID: 9727416 [TBL] [Abstract][Full Text] [Related]
17. Permeability of the blood-retinal and blood-aqueous barriers in galactose-fed rats. Caspers-Velu LE; Wadhwani KC; Rapoport SI; Kador PF J Ocul Pharmacol Ther; 1995; 11(3):469-87. PubMed ID: 8590278 [TBL] [Abstract][Full Text] [Related]
18. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Hotta N; Kawamori R; Fukuda M; Shigeta Y; Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139 [TBL] [Abstract][Full Text] [Related]
19. Effect of an aldose reductase inhibitor, CT-112, on healing of the corneal epithelium in galactose-fed rats. Awata T; Sogo S; Yamagami Y; Yamamoto Y J Ocul Pharmacol; 1988; 4(3):195-201. PubMed ID: 3143793 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of novel aldose reductase inhibitors: Effects on lens protein kinase Cgamma. Lewis S; Karrer J; Saleh S; Chan X; Tan Z; Hua D; McGill J; Pang YP; Fenwick B; Brightman A; Takemoto D Mol Vis; 2001 Jul; 7():164-71. PubMed ID: 11483892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]